Time is critical in drug development, which is why MediVector works to decrease both the time and costs of bringing drugs to market.
MediVector’s senior management team has directly driven numerous drugs through to FDA approval.
Our creative, effective, and entrepreneurial approach to drug development reduces the drug development cycle time and yields success.
MediVector’s strong development program is transitioning Favipiravir from being considered simply a treatment for a single indication to being hailed as a potential “One drug. Many bugs.” solution.
MediVector cut the development time for an anti-inflammatory drug for the treatment of asthma from 4.5 years to 1.5 years, saving significant time and cost.
MediVector helped achieve FDA approval for a therapeutic monoclonal antibody for treatment of B-cell chronic lymphocytic leukemia.